Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | XBP1 | P17861 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20908860 | 0.77 | MEN1 (0.32) | LMNAATM | |
| SCHEMBL24884816 | 0.76 | AKT1 (0.35) | LMNAMAPTXBP1ATMSMN1; SMN2 | |
| SCHEMBL19300441 | 0.72 | AKT1 (0.38) | LMNAMAPTATM | |
| SCHEMBL21229634 | 0.72 | MAPT (0.43) | LMNAMAPTSMN1; SMN2 | |
| SCHEMBL22036325 | 0.72 | LMNA (0.36) | LMNAMAPTATMSMN1; SMN2 | |
| SCHEMBL20625867 | 0.72 | MEN1 (0.32) | LMNAATM | |
| SCHEMBL22071895 | 0.72 | LMNA (0.36) | LMNAMAPTATMSMN1; SMN2 | |
| SCHEMBL24975608 | 0.69 | AKT1 (0.33) | ATM | |
| SCHEMBL21390836 | 0.69 | — | — | |
| SCHEMBL22334942 | 0.67 | MAPT (0.35) | LMNAMAPTXBP1ATMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143377-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | ELI LILLY AND COMPANY | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143377-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | LMNA 819/4885MAPT 568/4885XBP1 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.